Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 1
2005 1
2006 2
2007 3
2008 2
2009 1
2010 3
2011 4
2012 3
2013 2
2014 1
2015 3
2017 6
2018 7
2019 10
2020 4
2021 7
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Frontiers in PROTACs.
Hughes GR, Dudey AP, Hemmings AM, Chantry A. Hughes GR, et al. Among authors: chantry a. Drug Discov Today. 2021 Oct;26(10):2377-2383. doi: 10.1016/j.drudis.2021.04.010. Epub 2021 Apr 17. Drug Discov Today. 2021. PMID: 33872800 Review.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
Time to redefine Myeloma.
Pratt G, Bowcock S, Chantry A, Cook G, Jackson G, Lai M, Low E, Mulholland N, Owen R, Rabin N, Ramasamy K, Snowden JA, Streetly M, Wechalekar A, Yong K, Bird J. Pratt G, et al. Among authors: chantry a. Br J Haematol. 2015 Oct;171(1):1-10. doi: 10.1111/bjh.13620. Epub 2015 Jul 27. Br J Haematol. 2015. PMID: 26221971 Free article.
Metastatic Infiltration of Nervous Tissue and Periosteal Nerve Sprouting in Multiple Myeloma-Induced Bone Pain in Mice and Human.
Diaz-delCastillo M, Palasca O, Nemler TT, Thygesen DM, Chávez-Saldaña NA, Vázquez-Mora JA, Ponce Gomez LY, Jensen LJ, Evans H, Andrews RE, Mandal A, Neves D, Mehlen P, Caruso JP, Dougherty PM, Price TJ, Chantry A, Lawson MA, Andersen TL, Jimenez-Andrade JM, Heegaard AM. Diaz-delCastillo M, et al. Among authors: chantry a. J Neurosci. 2023 Jul 19;43(29):5414-5430. doi: 10.1523/JNEUROSCI.0404-23.2023. Epub 2023 Jun 7. J Neurosci. 2023. PMID: 37286351 Free PMC article.
Multiple myeloma-A painful disease of the bone marrow.
Diaz-delCastillo M, Chantry AD, Lawson MA, Heegaard AM. Diaz-delCastillo M, et al. Among authors: chantry ad. Semin Cell Dev Biol. 2021 Apr;112:49-58. doi: 10.1016/j.semcdb.2020.10.006. Epub 2020 Nov 4. Semin Cell Dev Biol. 2021. PMID: 33158730 Review.
Myeloma Bone Disease: The Osteoblast in the Spotlight.
Andrews RE, Brown JE, Lawson MA, Chantry AD. Andrews RE, et al. Among authors: chantry ad. J Clin Med. 2021 Sep 2;10(17):3973. doi: 10.3390/jcm10173973. J Clin Med. 2021. PMID: 34501423 Free PMC article. Review.
65 results